ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ELDN / news
KROS (64) SIGA (68) NATR (64) SLGL (48) ⌘ Pro Terminal →

Why ELDN Stock dropped -5.41% Today — RQD Quant Desk Flash

$2.62 -5.41% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.59

Eledon Pharmaceuticals Inc. (ELDN) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $212.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ELDN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ELDN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Eledon Pharmaceuticals Inc. (NASDAQ: ELDN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $2.62 (-5.41% 1D, market cap $212.9M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ELDN ranks #536 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ELDN compare to KROS and SIGA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ELDN carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KROS (Keros Therapeutics Inc.) holds a C grade (64/100 RQD, P/E N/A, ROIC 85.0%, cap $213.3M) and SIGA (SIGA Technologies Inc.) posts a C+ grade (68/100 RQD, P/E 9.8x, ROIC 42.7%, cap $212.0M). Among the 5-stock peer group, SIGA leads on earnings multiple (9.8x) while KROS leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ELDN?
▼

Per ELDN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001404281), Eledon Pharmaceuticals Inc. generated $71.0M in revenue (-4.7% YoY), -$45.6M in net income, and -$62.3M in free cash flow against $169.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.59 (-1.16%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510037
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D
Cash (5)Whales (9)SEC (10)Macro (8)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-9.5% Base Target
$5 Bull$2 Base$2 Bear
📬 FREE ELDN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ELDN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (37/100 Composite)
🔍 WHY ELDN SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (24% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
29
Grade E$2.25+0.4% Next Q
Q2 (-2Q)
32
Grade E$2.26+22.1% Next Q
Q3 (-1Q)
34
Grade E$2.76-5.1% Next Q
Current
37
Grade D-$2.62-8.1% Hist 90D α
Trajectory: E (29) → D- (37)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ELDN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ELDN currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.65) and Max Pain ($2.75) forces dealer call-delta covering toward $4.71.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ELDN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ELDN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 37%NO 63%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why ELDN Stock dropped -5.41% Today — RQD Quant Desk Flash

Eledon Pharmaceuticals Inc. (ELDN) dropped -5.41% to $2.62, trading at 40% of its 52-week range ($1.35 – $4.49). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 40% of its 52-week range ($1.35 – $4.49) with RSI-14 at 51 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $2.62 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live ELDN Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ELDN)

  • ✓Walkthrough of ELDN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ELDN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -30.69%▼ DESCENDING CHANNEL
2026-11-04O $2.77H $2.77L $2.62C $2.62VOL 672.7K
RES: $3.16SUP: $1.86SMA50: $2.65SMA200: $3.12
$4.66$3.97$3.28$2.59$1.90RES $3.16SUP $1.86$2.622026-05-052026-06-182026-08-052026-09-212026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ELDN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ELDN Butterfly Map → + Track ELDN →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -4.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ELDN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ELDN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ELDN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ELDN)

Health Care Rank #536 of 1015 ⚔️ KROS vs ELDN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ELDN vs. KROS, SIGA, NATR, SLGL)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Eledon Pharmaceuticals Inc. (ELDN) ranks #536 by composite RQD confidence (37/100, grade D-) and #561 by equity capitalization ($212.9M). Within this direct 5-issuer industry benchmark cohort, SIGA leads on earnings valuation at 9.8x trailing P/E, while KROS leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. SIGA currently holds the highest overall quantitative score in the immediate peer group at 68/100 (C+) compared with ELDN at 37/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ELDN ACTIVE
Eledon Pharmaceuticals Inc.
D- 37/100 — — -35.0% -5.41% $212.9M Benchmark Subject
KROS
Keros Therapeutics Inc.
C 64/100 — — 85.0% -2.54% $213.3M /kros-vs-eldn →
SIGA
SIGA Technologies Inc.
C+ 68/100 9.8x 68.6% 42.7% -2.96% $212.0M /siga-vs-eldn →
NATR
Nature's Sunshine Products Inc.
C 64/100 11.1x 72.4% 28.9% -1.88% $211.5M /natr-vs-eldn →
SLGL
Sol-Gel Technologies Ltd.
D 48/100 — — -35.0% -3.89% $215.1M /slgl-vs-eldn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001404281 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Eledon Pharmaceuticals Inc. (ELDN) reported GAAP revenue of $71.0M (-4.7% vs. FY2024 revenue of $74.5M , and -41.0% cumulative change since FY2023) , GAAP net income of -$45.6M, operating cash flow of -$62.3M, and free cash flow of -$62.3M (-31.9% YoY). On the balance sheet, ELDN closed FY2025 with $169.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $71.0M -$45.6M -$62.3M -$62.3M $169.0M —
FY2024 (FY) 2024-12-31 $74.5M -$36.2M -$47.3M -$47.3M $177.4M —
FY2023 (FY) 2023-12-31 $120.4M -$116.5M -$39.5M -$39.5M — —

3. ELDN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ELDN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Eledon Pharmaceuticals Inc. (NASDAQ: ELDN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $2.62 (-5.41% 1D, market cap $212.9M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ELDN ranks #536 in composite RQD confidence.

How does ELDN compare to KROS and SIGA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ELDN carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KROS (Keros Therapeutics Inc.) holds a C grade (64/100 RQD, P/E N/A, ROIC 85.0%, cap $213.3M) and SIGA (SIGA Technologies Inc.) posts a C+ grade (68/100 RQD, P/E 9.8x, ROIC 42.7%, cap $212.0M). Among the 5-stock peer group, SIGA leads on earnings multiple (9.8x) while KROS leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ELDN?

Per ELDN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001404281), Eledon Pharmaceuticals Inc. generated $71.0M in revenue (-4.7% YoY), -$45.6M in net income, and -$62.3M in free cash flow against $169.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ELDN trading relative to its 50-day, 200-day, and 52-week technical levels?

ELDN last traded at $2.62 (-5.41% on volume of 672,710 shares), positioning the stock -1.13% below its 50-day simple moving average ($2.65) and -16.03% below its 200-day simple moving average ($3.12). Across its 52-week range of $1.35 to $4.49, ELDN sits at the 40.4% percentile with a 14-day RSI of 51.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.29 to $2.95).

Direct Sub-Reports: ELDN RQD Cockpit ELDN 12M Forecast ELDN Earnings & Move ELDN Dividends & DRIP ELDN Insiders & 13F ELDN Whale Options ELDN Profit Sankey ELDN News & Why
ROARABLE RATING BRIEF • RQD 37/100 (D-) ✓ SEC XBRL & RQD VERIFIED

ELDN — Eledon Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Eledon Pharmaceuticals Inc. (ELDN) earns a live Roarable RQD composite score of 37/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $2.62 (-5.41% 1D, market capitalization $212.9M).

  • Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (9/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Eledon Pharmaceuticals Inc. (ELDN) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry,. The profile states the company has a market capitalization of $0.2B. Reported revenue is — across the three periods shown, so the company's monetization model is not identifiable from the provided data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Eledon Pharmaceuticals Inc. (ELDN) reported $71.0M in annual revenue (up from $74.5M in FY2024, -4.7% YoY) and -$45.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($120.4M revenue, -$116.5M net income) through FY2025, ELDN scaled operating cash flow to -$62.3M and free cash flow to -$62.3M, backed by $169.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 37/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 9/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $1.35 – $4.49 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Sector: Health Care; Industry: Biotechnology: Pharmaceutical Preparations. The beta of 1.0 (per market data) is the only sector-sensitivity measure provided.

  • Key Question #1: Can ELDN sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $71.0M and free cash flow of -$62.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is ELDN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ELDN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Eledon Pharmaceuticals Inc. (ELDN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ELDN Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ELDN Bull vs. Bear Conversation Board — What's Your Call at $2.62?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ELDN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ELDN:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $3.35 (+20.9%)
📌 Pinned Debate

The stock sits near the low end of its 52-week range at $3.04 with reported Phase 2 BESTOW quality-of-life data cited in recent news as

The stock sits near the low end of its 52-week range at $3.04 with reported Phase 2 BESTOW quality-of-life data cited in recent news as a potential catalyst.. When you look under the hood at ELDN, Fundamental Cash Engine is 5/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (9/20) has been quietly accumulating below $4.60. My 12M target is $3.35.

RetailWhale_TX 🐂 BULL

Both sides have a point here — ELDN's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $2.38 (-14.1%)
Spot @ $2.77

Negative free cash flow of -$62.3M in FY 2025, a Piotroski F-Score of 1 out of 9, and a ROIC of -35% signal a weak cash engine and bala

Careful chasing ELDN at $2.77. Negative free cash flow of -$62.3M in FY 2025, a Piotroski F-Score of 1 out of 9, and a ROIC of -35% signal a weak cash engine and balance sheet.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $2.38 on multiple compression.

LIVE TAPE